Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients

Clinical Pharmacokinetics

Volumn 44, Issue 9, 2005, Pages 957-967

  Shamseddine, Ali I ^a   Khalifeh, Mohammad J ^a   Mourad, Fadi H ^a   Chehal, Aref A ^a   Al Kutoubi, Aghiad ^a   Abbas, Jaber ^a   Habbal, Mohammad Z ^a   Malaeb, Lida A ^a   Bikhazi, Anwar B ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; LY 264368; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SURGERY; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEAMINATION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; FEMALE; HUMAN; MALE; PANCREAS CANCER; PLASMA; PRIORITY JOURNAL; SPLEEN ARTERY; SURVIVAL; VENOUS BLOOD;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; HUMANS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 24344496010     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544090-00005     Document Type: Article

References (22)

1. Gold EB, Cameron JL. Chronic pancreatitis and pancreatic cancer. N Engl J Med 1993; 328: 1485-6
2. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 1987; 60: 2284-303
3. Burris III HA, Moore MJ, Andersen J, et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13
4. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action and self-potentiation. Semin Oncol 1995; 22: 3-10
5. Kiani A, Köhne CH, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol 2003; 51: 266-70
6. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002; 5: 19-33
7. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992; 52: 533-9
8. Goldberg JA, Kerr DJ, Willmott N, et al. Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer 1988; 57: 186-9
9. Aigner KR, Gailhofer S, Kopp S. Regional versus systemic chemotherapy for advanced pancreatic cancer: a randomized study. Hepatogastroenterology 1998; 45: 1125-9
10. Homma H, Doi T, Mezawa S, et al. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 2000; 89: 303-13
11. Laufer M, Ramalingam S, Schoenberg MP, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003; 21: 697-703
12. Weissmann A, Ludwig H. Intra-arterial gemcitabine for treatment of inoperably pancreatic and cholangio carcinoma [abstract no. 1170]. Proc Am Soc Clin Oncol; 1999; 18: 305
13. Spagnuolo P, Roversi R, Rossi G, et al. Phase II study of gemcitabine as locoregional treatment of advanced pancreatic cancer [abstract no. 1153]. Proc Am Soc Clin Oncol; 1999; 18: 300a
14. Clemente CD. Clemente anatomy: a regional atlas of the human body. 4th ed. Baltimore (MD): Williams and Wilkins, 1997: 151
15. Abbruzzese JL, Grunewald R, Weeks EA, et al. Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8
16. Rowland M, Tozer T. Clinical pharmacokinetics: concepts and applications. 2nd ed. Beckenham: Lea & Febiger, 1989: 380, 459
17. Wagner JG. Biopharmaceutics and relevant pharmacokinetics. 1st ed. Hamilton (IL): Drug Intelligence Publications, 1971: 294
18. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2: 498-504
19. Ensminger WD. Intra-arterial therapy. In: Perry MC, editors. The chemotherapy source book. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 164-74
20. Theodors A, Bukowski RM, Hewlett JS, et al. Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma: phase I and II pilot study. Am J Clin Oncol 1982; 5: 555-8
21. Smith L, Gazet J. Intraarterial chemotherapy for patients with inoperable carcinoma of the pancreas. Ann R Coll Surg Engl 1980; 62: 208-12
22. Malayeri R, Wein W, Zielinski C. Effective intrahepatic administration of gemcitabine after failure of doxorubicin in metastatic breast cancer [letter]. Eur J Cancer 1997; 33 (14): 2435